Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 31, 2024, to report its financial and operating results for the third quarter ended September 30, 2024. The key information is contained within the press release, furnished as Exhibit 99.1, which details the company's performance during the period. Investors should refer to this press release for specific financial metrics, revenue figures, and operational updates. While the 8-K itself is a procedural filing, the attached press release is the substantive document for understanding Regeneron's third-quarter performance. This filing serves as the official notification of these results to the market, and the press release provides the necessary details to assess the company's progress and financial health as of the end of September 2024.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. (REGN) announced its third-quarter 2024 financial and operating results via an 8-K filing on October 31, 2024.
- 2The key details of the third-quarter performance are provided in the press release attached as Exhibit 99.1.
- 3The filing covers the financial and operational results for the period ending September 30, 2024.
- 4Investors are directed to the furnished press release for specific financial metrics and operational updates.
- 5This 8-K filing is primarily procedural, with the substantive information contained in the accompanying press release.